{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:47:17Z","timestamp":1793303237819,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Zhejiang Provincial Natural Science Foundation of China","award":["grant number LQ24H090009"],"award-info":[{"award-number":["grant number LQ24H090009"]}]},{"name":"the Medical and Health Science and Technology Project of Zhejiang Province","award":["2024KY539"],"award-info":[{"award-number":["2024KY539"]}]},{"name":"Taizhou University Medical Special Research Project","award":["G2023FSXY05"],"award-info":[{"award-number":["G2023FSXY05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-024-06084-5","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:02:07Z","timestamp":1727438527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["APOE contributes to longitudinal impulse control disorders progression in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Linxi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"7","key":"6084_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"6084_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","volume":"16","author":"V Voon","year":"2017","unstructured":"Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO. Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update. Lancet Neurol. 2017;16(3):238\u201350.","journal-title":"Lancet Neurol"},{"issue":"4","key":"6084_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/mds.27668","volume":"34","author":"D Weintraub","year":"2019","unstructured":"Weintraub D. Impulse control disorders in Parkinson\u2019s disease: a 20-year odyssey. Mov Disord. 2019;34(4):447\u201352.","journal-title":"Mov Disord"},{"issue":"1","key":"6084_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/appi.ajp.2018.18040465","volume":"176","author":"D Weintraub","year":"2019","unstructured":"Weintraub D, Mamikonyan E. Impulse control disorders in Parkinson\u2019s disease. Am J Psychiatry. 2019;176(1):5\u201311.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"6084_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","volume":"88","author":"A Antonini","year":"2017","unstructured":"Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2017;88(4):317\u201324.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"6084_CR6","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"JC Corvol","year":"2018","unstructured":"Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189\u2013201.","journal-title":"Neurology"},{"issue":"4","key":"6084_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00702-012-0934-4","volume":"120","author":"F Cormier","year":"2013","unstructured":"Cormier F, Muellner J, Corvol JC. Genetics of impulse control disorders in Parkinson\u2019s disease. J Neural Transm (Vienna). 2013;120(4):665\u201371.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"6084_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mds.23501","volume":"26","author":"A Antonini","year":"2011","unstructured":"Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, Caporali A, Mancini F, Pezzoli G, Ceravolo R, et al. Impulsivity and compulsivity in drug-naive patients with Parkinson\u2019s disease. Mov Disord. 2011;26(3):464\u20138.","journal-title":"Mov Disord"},{"key":"6084_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/bs.irn.2017.05.029","volume":"133","author":"EW Lim","year":"2017","unstructured":"Lim EW, Tan EK. Genes and nonmotor symptoms in Parkinson\u2019s disease. Int Rev Neurobiol. 2017;133:111\u201327.","journal-title":"Int Rev Neurobiol"},{"issue":"4","key":"6084_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41582-020-0335-5","volume":"16","author":"I Fyfe","year":"2020","unstructured":"Fyfe I. APOE(*)epsilon4 promotes synucleinopathy. Nat Rev Neurol. 2020;16(4):185.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"6084_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"6084_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/mds.22472","volume":"24","author":"G Santangelo","year":"2009","unstructured":"Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson\u2019s disease. Mov Disord. 2009;24(6):899\u2013905.","journal-title":"Mov Disord"},{"issue":"11","key":"6084_CR13","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/npp.2010.84","volume":"35","author":"CR Housden","year":"2010","unstructured":"Housden CR, O\u2019Sullivan SS, Joyce EM, Lees AJ, Roiser JP. Intact reward learning but elevated delay discounting in Parkinson\u2019s disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology. 2010;35(11):2155\u201364.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"6084_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00213-009-1697-y","volume":"207","author":"V Voon","year":"2010","unstructured":"Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V, Fernandez H, Potenza MN, Dolan RJ, Hallett M. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology. 2010;207(4):645\u201359.","journal-title":"Psychopharmacology"},{"key":"6084_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fneur.2018.00654","volume":"9","author":"A Martini","year":"2018","unstructured":"Martini A, Dal Lago D, Edelstyn NMJ, Grange JA, Tamburin S. Impulse control disorder in Parkinson\u2019s disease: a meta-analysis of cognitive, affective, and motivational correlates. Front Neurol. 2018;9:654.","journal-title":"Front Neurol"},{"issue":"12","key":"6084_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, et al. The Parkinson\u2019s progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5(12):1460\u201377.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"6084_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mds.26374","volume":"31","author":"MA Nalls","year":"2016","unstructured":"Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB. Parkinson\u2019s progression marker initiative I: baseline genetic associations in the Parkinson\u2019s progression markers initiative (PPMI). Mov Disord. 2016;31(1):79\u201385.","journal-title":"Mov Disord"},{"issue":"10","key":"6084_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord. 2009;24(10):1461\u20137.","journal-title":"Mov Disord"},{"issue":"15","key":"6084_CR19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","volume":"86","author":"G Pagano","year":"2016","unstructured":"Pagano G, Ferrara N, Brooks DJ, Pavese N. Age at onset and Parkinson disease phenotype. Neurology. 2016;86(15):1400\u20137.","journal-title":"Neurology"},{"issue":"1","key":"6084_CR20","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000006692","volume":"92","author":"R Kim","year":"2019","unstructured":"Kim R, Lee J, Kim HJ, Kim A, Jang M, Jeon B, Kang UJ. CSF beta-amyloid(42) and risk of freezing of gait in early Parkinson disease. Neurology. 2019;92(1):e40\u20137.","journal-title":"Neurology"},{"key":"6084_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.parkreldis.2020.10.033","volume":"81","author":"R Kim","year":"2020","unstructured":"Kim R, Shin JH, Park S, Kim HJ, Jeon B. Apolipoprotein E epsilon4 genotype and risk of freezing of gait in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2020;81:173\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"6084_CR22","first-page":"726","volume":"17","author":"I Fyfe","year":"2021","unstructured":"Fyfe I. APOE epsilon4 influences Parkinson disease progression. Nat Rev Neurol. 2021;17(12):726.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"6084_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mds.28805","volume":"37","author":"JL Pu","year":"2022","unstructured":"Pu JL, Jin CY, Wang ZX, Fang Y, Li YL, Xue NJ, Zheng R, Lin ZH, Yan YQ, Si XL, et al. Apolipoprotein E genotype contributes to motor progression in Parkinson\u2019s disease. Mov Disord. 2022;37(1):196\u2013200.","journal-title":"Mov Disord"},{"key":"6084_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neulet.2016.02.042","volume":"618","author":"FN Emamzadeh","year":"2016","unstructured":"Emamzadeh FN, Aojula H, McHugh PC, Allsop D. Effects of different isoforms of apoE on aggregation of the alpha-synuclein protein implicated in Parkinson\u2019s disease. Neurosci Lett. 2016;618:146\u201351.","journal-title":"Neurosci Lett"},{"issue":"2","key":"6084_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12031-017-0967-0","volume":"63","author":"FN Emamzadeh","year":"2017","unstructured":"Emamzadeh FN, Allsop D. Alpha-synuclein interacts with lipoproteins in plasma. J Mol Neurosci. 2017;63(2):165\u201372.","journal-title":"J Mol Neurosci"},{"issue":"3\u20134","key":"6084_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12031-017-0942-9","volume":"62","author":"FN Emamzadeh","year":"2017","unstructured":"Emamzadeh FN. Role of apolipoproteins and alpha-synuclein in Parkinson\u2019s disease. J Mol Neurosci. 2017;62(3\u20134):344\u201355.","journal-title":"J Mol Neurosci"},{"key":"6084_CR27","doi-asserted-by":"crossref","unstructured":"Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, Meneses AD, Li F, Shue F, Zheng J et al. APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12(529).","DOI":"10.1126\/scitranslmed.aay1809"},{"issue":"4","key":"6084_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","volume":"16","author":"C Peng","year":"2020","unstructured":"Peng C, Trojanowski JQ, Lee VM. Protein transmission in neurodegenerative disease. Nat Rev Neurol. 2020;16(4):199\u2013212.","journal-title":"Nat Rev Neurol"},{"key":"6084_CR29","doi-asserted-by":"publisher","first-page":"635494","DOI":"10.3389\/fpsyt.2021.635494","volume":"12","author":"JF Zhang","year":"2021","unstructured":"Zhang JF, Wang XX, Feng Y, Fekete R, Jankovic J, Wu YC. Impulse control disorders in Parkinson\u2019s disease: epidemiology, pathogenesis and therapeutic strategies. Front Psychiatry. 2021;12:635494.","journal-title":"Front Psychiatry"},{"issue":"7673","key":"6084_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523\u20137.","journal-title":"Nature"},{"issue":"16","key":"6084_CR31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383.","journal-title":"JAMA"},{"issue":"5","key":"6084_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589\u201395.","journal-title":"Arch Neurol"},{"issue":"6","key":"6084_CR33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ana.22356","volume":"69","author":"V Voon","year":"2011","unstructured":"Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, Stacy M. Impulse control disorders in Parkinson disease: a multicenter case\u2013control study. Ann Neurol. 2011;69(6):986\u201396.","journal-title":"Ann Neurol"},{"issue":"2","key":"6084_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2015;30(2):121\u20137.","journal-title":"Mov Disord"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:13:05Z","timestamp":1727439185000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6084"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06084-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study did not require an ethical board approval or patient consent because it was based on publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"632"}}